Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

(2018) Gerald F Watts et al.   EUROPEAN HEART JOURNAL

The metabolism of lipoprotein (a): an ever-evolving story

(2017) Gissette Reyes-Soffer et al.   JOURNAL OF LIPID RESEARCH

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E

(2017) John S. Millar et al.   JOURNAL OF LIPID RESEARCH

Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis

(2017) Danish Saleheen et al.   Lancet Diabetes & Endocrinology

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinSignificance

(2016) Gissette Reyes-Soffer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United StatesHighlights

(2016) Steve Varvel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role

(2016) Frederick J. Raal et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

(2016) Gissette Reyes-Soffer et al.   Science Translational Medicine

Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes MellitusSignificance

(2015) Esther M. Ooi et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance

(2015) Raul D. Santos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

(2015) John S. Millar et al.   JOURNAL OF CLINICAL INVESTIGATION

Lipoprotein (a) measurements for clinical application

(2015) Santica M. Marcovina et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein(a) metabolism

(2014) Stefania Lamon-Fava et al.   CURRENT OPINION IN LIPIDOLOGY

Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry

(2013) Haihong Zhou et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study

(2013) Pia R Kamstrup et al.   Lancet Diabetes & Endocrinology

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus

(2009) Gissette Reyes-Soffer et al.   JOURNAL OF LIPID RESEARCH

The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism

(2008) Henry N. Ginsberg et al.   JOURNAL OF LIPID RESEARCH

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

(2008) Claes Bergmark et al.   JOURNAL OF LIPID RESEARCH